SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-0.61%171.920.4%$140.02m
JAZZJazz Pharmaceuticals Plc
-1.00%175.342.2%$121.59m
SAGESAGE Therapeutics, Inc.
0.02%168.669.6%$113.01m
PRGOPerrigo Co. Plc
0.25%76.026.7%$91.90m
ENDPEndo International Plc
-0.23%11.198.9%$74.19m
MNKMallinckrodt Plc
-1.01%21.6821.1%$71.54m
ZGNXZogenix, Inc.
-1.19%58.2511.9%$66.66m
ICPTIntercept Pharmaceuticals, Inc.
-1.33%94.4621.8%$66.52m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.51%146.366.8%$62.66m
CTLTCatalent Inc
1.22%43.872.6%$61.89m
SUPNSupernus Pharmaceuticals, Inc.
0.65%54.606.3%$40.11m
MDCOMedicines Company
-0.50%39.8821.8%$39.82m
UTHRUnited Therapeutics Corporation
0.28%124.4414.4%$37.25m
PTLAPortola Pharmaceuticals, Inc.
-0.15%39.867.7%$34.94m
AERIAerie Pharmaceuticals, Inc.
-0.14%73.807.9%$30.80m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.